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Abstract 
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to 
the large size, poor protein stability and extensive post-translational modifications. As 
a consequence, efficient production of FVIII in mammalian cells poses a major 
challenge, with typical yields 2-3 orders of magnitude lower than for antibodies. In the 
present study we investigated CHO DXB11 cells transfected with a plasmid encoding 
human coagulation factor VIII. Single cell clones were isolated from the pool of 
transfectants and a panel of 14 clones representing a dynamic range of FVIII 
productivities was selected for RNA sequencing analysis. The analysis showed distinct 
differences in F8 RNA composition between the clones. The exogenous F8-dhfr 
transcript was found to make up the most abundant transcript in the present clones. 
No correlation was seen between F8 mRNA levels and the measured FVIII productivity. 
It was found that three MTX resistant, non-producing clones had different truncations 
of the F8 transcripts. We find that by using deep sequencing, in contrast to microarray 
technology, for determining the transcriptome from CHO transfectants, we are able to 
accurately deduce the mature mRNA composition of the transgene and identify 
significant truncations that would probably otherwise have remained undetected.   
1 Introduction 
Coagulation factor VIII (FVIII) is a 170-280 kDa glycoprotein that plays a vital role in 
blood coagulation. Deficiency of FVIII results in the congenital bleeding disorder 
Haemophilia A which can be treated by infusion of plasma-derived or recombinant 
FVIII [1]. Recombinant production of FVIII is preferred due to virus risk associated with 
blood products. However, recombinant FVIII is one of the most challenging 
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therapeutics to produce due to the size of the FVIII protein, the multitude of post-
translational modifications, and the low yields obtained [2].  
 
Endogenous FVIII is synthesized as a single-chain precursor peptide that is processed 
into a heterodimer consisting of a heavy and a light chain connected by a metal ion 
bridge [3,4]. Due to heterogeneous proteolytic processing of the heavily glycosylated B 
domain, in the C-terminal part of the heavy chain the molecular weight of the heavy 
chain is highly variable [5]. The function of the B domain remains to be determined, as 
FVIII with and without B domain has the same haemostatic effect [6]. Shortening of 
the 904 amino acid B domain to a minimal B domain of 10-30 amino acids reduces the 
complexity and increases the yield of recombinant FVIII [7-9]. Still, typical yields of 
recombinant FVIII from standard mammalian production cell lines such as Chinese 
hamster ovary (CHO) cells are 100-1000 fold lower than the yields routinely obtained 
with recombinant antibodies from the same cells [6]. 
 
Generation of mammalian cell lines for production of recombinant protein typically 
involves the transfection of a suitable cell line with an expression construct encoding 
the gene of interest and the subsequent selection and screening to isolate cell clones 
that have incorporated the exogenous expression cassette into their genome. 
Different clones exhibit a wide variation in productivity, genetic stability, and 
performance in a production setting [10]. The productivity of mammalian cell clones 
are known to be influenced by the composition of the expression vector, the site of 
insertion in the host cell genome, the metabolic and growth characteristics of the 
clone, and the cultivation conditions [10]. Several different plasmid systems exist. For 
the current study we employed use of an IRES element [11] to allow for coupled 
translation of both a gene of interest and a selection marker from the same bicistronic 
mRNA [12]. 
 
In recent years, microarray analysis has allowed investigation and comparison of the 
transcriptome of mammalian production cell lines [13-15]. With the advances within 
deep sequencing and the publication of CHO genomes [16-18] (see recent review [19]) 
it is now possible to analyze the transcriptome with a much higher level of detail [20-
22]. 
 
In the present study, we compare the growth, metabolic profile and FVIII productivity 
of a selection of CHO cell clones and utilize deep sequencing to relate these features to 
the transcription of the individual elements in the vector cassette directing the 
expression of FVIII and the selection marker. To our knowledge, this is the first report 
on the use of deep sequencing to reveal detailed variations of the mRNA transcribed 
from the exogenous expression cassette in mammalian production cell lines.  
2 Materials and methods 
2.1 Cell culture 
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CHO DXB11 cells were transfected with a plasmid encoding FVIII by electroporation 
(GenePulser Xcell, Biorad). The plasmid contained the adenovirus-2 major late 
promotor, the adenovirus-2 late mRNA tripartite leader, a 3’ end and 5’ end intron 
sequence with splice junction, the ORF of F8 with a minimal artificial B-domain [23], an 
internal ribosomal entry site (IRES), the dhfr ORF, and a poly A signal, similar to 
constructs used elsewhere [24,25]. Cells were adapted to MTX and subsequently single 
cell cloned by limiting dilution. Productivity of 59 clones was measured by seeding at 
3x105 cells/ml in 30ml of HyClone CDM4CHO media (Thermo) supplemented with 
Penicillin/Streptomycin (Gibco) and MTX, and cultured for 72 hours before measuring 
FVIII chromogenic activity (see assays). In order to get the broadest range of 
productivities, a mother clone (Clone 3) from a previous transfection created under 
similar conditions as above as well as two sub clones (Clone 1 and 2) created by single 
cell dilution of clone 3, were included in the panel of clones. The 14 selected clones 
seeded at 3x105 cells/ml in 75 ml of HyClone CDM4CHO (Thermo) supplemented with 
Penicillin/Streptomycin (Gibco), L-glutamine supplement (SAFC Biosciences) and MTX. 
The cells were grown in an orbital shaker at 36.5˚C at a shaking speed of 125 rpm and 
8.0% CO2. Nine clones (1-3, 6-8 and 12-14) were grown in triplicates and the remaining 
5 clones (4, 5, 9, 10 and 11) in single cultures bringing the total up to 32 cultures. The 
cultures were randomized prior to sampling in order to avoid bias.  
 
2.2 Assays 
Cell number and viability were measured using a Vicell XR system (Beckman Coulter). 
Metabolites were measured using a BioProfile 100 Plus (Nova Biopmedical). The 
activity of FVIII was measured as chromogenic activity using an in-house version of the 
Coatest SP (Chromogenix, Instrumentation Laboratory, Milano, Italy)[26]. Protein 
lysates for Western blotting were prepared by spinning down 10e6 cells and 
resuspending the pellet in 200 μl of Mammalian Protein Extraction Reagent (M-PER) 
(Thermo) following manufacturer’s instructions. 30 μg of each sample was used for 
Western blotting. Gels were submitted to western blotting using Novex/NuPage 
blotting system (Invitrogen). Primary antibodies used were 1:500 dilution of sheep 
polyclonal anti-human factor VIII (CL20035AP, Cedarlane labs, Burlington, ON, Canada) 
and 1:1000 dilution of rabbit anti-beta-actin antibody (Cell Signaling Technology, 
Danvers, Ma, USA). Secondary antibodies used were 1:20000 dilution of Donkey anti-
Rabbit IRDye® 800 CW (LI-COR® Biosciences, Lincoln, Ne, USA) and 1:10000 dilution of 
Alexa Fluor® 680 donkey anti-sheep IgG (Invitrogen, Carlsbad, Ca, USA). The ladders 
used were Full Range Rainbow™ recombinant protein molecular weight marker (Ge 
lifescience, Piscataway, NJ, USA). 
 
2.3 RNA purification and next-generation sequencing 
After 48 hours of cultivation RNA was extracted from 2x106 cells using TRIzol 
(Invitrogen) the RNeasy Cleanup kit (Qiagen) following the manufacturer’s instructions. 
RNA integrity was confirmed on an Agilent 2100 Bioanalyzer using total RNA nano 
chips (Agilent Technologies, Santa Clara, Ca, USA). RNA concentration was measured 
using a NanoDrop spectrophotometer (NanoDrop Technologies). Multiplexed cDNA 
library generation using the TruSeq RNA Sample Preparation Kit v2 (Illumina, Inc., San 
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Diego, CA) and next-generation sequencing were performed by AROS Applied 
Biotechnology (Aarhus, Denmark) using 8 samples per lane in an Illumina Hiseq 2000 
system for paired-end sequencing. Clone 1, 8, 12, 13 and 14 were processed and 
analyzed by Cergentis (Utrecht, Netherlands) with their Targeted Locus Amplification 
(TLA) Technology [27] for targeted sequencing of the transgene and transgene 
integration site 
 
2.4 Treatment of next-generation sequencing data 
The FASTQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was 
used to evaluate the quality of the fastq files before and after treatment. The FASTX 
Toolkit (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to 
remove the adaptamers (fastx_trimmer) and trim the ends for basepairs with a quality 
score lower than 20 (fastq_quality_trimmer). An in house algorithm was used to 
intersect the read-pairs after quality trimming. The reads were aligned to the CHO-K1 
genome (downloaded from Genbank as assembly GCF_000223135.1), combined with 
an extra scaffold containing the transgene, using tophat2 [28] and reads were counted 
using HTseq (http://www-huber.embl.de/users/anders/HTSeq). The samples were 
normalised using EdgeR [29] in R [30] and the CPM values given in EdgeR were 
normalized by gene length in order to calculate the FPKM-values. The Pearson 
correlation was calculated for expression level of F8 and dhfr to the FVIII productivity 
defined as chromogenic activity measured at 48 hours into the cultivation normalized 
by the viable cell count. RNA composition across the transgenes was measured by 
GenomeCoverageBed from BEDTools (version 2.16.2). 
 
2.5 qRT-PCR 
cDNA was produced from 1µg RNA from each of the 32 samples sent to RNA 
sequencing using SuperScript III first-strand synthesis supermix (Invitrogen, Carlsbad, 
CA). Primers designed for the tripartite leader (transgene position 1119-1136 and 
1193-1215), the F8 ORF (transgene position 1676-1695 and 1752-1775), the dhfr ORF 
(transgene position 6750-6769 and 6886-6905) and gapdh (Forward: 
AACTTTGGCATTGTGGAAGG and reverse: ACACGTTGGGGGTAGGAACA). The qRT-PCR 
reaction was run as 20µl reaction using Quantifast SYBR green PCR Master Mix 
(QIAGEN, Germany) following manufacturer’s instructions on a Stratagene MX3000P 
real-time PCR system (Stratagene). Primer efficiencies were calculated based on 5 
consecutive 5-fold dilutions of cDNA sample yielding efficiencies of 101% for gapdh, 
107% for dhfr, 96% of F8 and 93% for tripartite leader. The relative expression ratio for 
the tripartite leader, F8 and dhfr was calculated compared to sample 1 from clone 1 as 
described elsewhere [31].  
 
2.6 Genomic PCR 
CHO DXB11 cells were thawed from an in-house master cell bank. The cells were 
passaged in alpha MEM media with 10% FBS, 1% NEAA, 1% P/S. Genomic DNA from 
this mother cell line and from clone 3, clone 7 and clone 8 was extracted from 2 mio 
cells using DNeasy Blood & Tissue Kit (Qiagen) following manufacturer’s instructions. 
100ng of gDNA were used as template for a 25µl PCR reaction using KOD Xtreme™ Hot 
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Start DNA Polymerase (Milipore) following manufacturer’s instructions. Primers were 
designed for gapdh (same as used for qRT-PCR) and for spanning from the transgene 
to the surround genome: PCR1 (forward primer aligning to transgene position 4694-
4713 and reverse: GCAAAGAATGATCCCAGCTT), PCR2 (forward primer aligning to 
transgene position 4781-4800 and reverse: CCTTCCCTCCTCTCTTCCTG)  
3 Results  
3.1 RNA was extracted from exponentially growing cell 48 hours after seeding 
CHO DXB11 cells were transfected with a plasmid encoding human coagulation factor 
VIII (the F8 gene) and a dhfr selection marker from a bicistronic mRNA. The pool of 
transfectants were amplified and subsequently sorted into single cells. A selection of 
CHO DXB11 clones were analyzed for FVIII productivity and growth rate (Figure 1). 
From 62 clones, 14 clones exhibiting a dynamic range of FVIII productivities and were 
selected for further analysis (Figure 1). These clones were named clone 1-14 based on 
descending FVIII productivity. The three highest yielding clones (clone 1-3) were sub-
clones of the same clonal cell line. Clone 12-14 did not produce detectable FVIII levels 
and were classified as non-producers. 
 
When seeded at 3x105 cells/ml, most clones entered the exponential growth phase 
within 27 hours of cultivation and had not entered the stationary phase 73 hours after 
seeding (Figure 2A). The selected clones all had doubling times of 30-40 hours. During 
cultivation, cell growth medium glucose and glutamine levels gradually decreased, 
while lactate levels increased (Figure 2B). The glucose and glutamine levels dropped 
most rapidly in the medium of the faster growing clones (data not shown). For the FVIII 
producing clones, FVIII levels continuously increased during the first 100 hours of 
cultivation (Figure 2C) before stagnating or dropping. Based on these growth and 
production characteristics, we decided to extract RNA for analysis of the transcriptome 
after 48 hours of cultivation. At this time point, all cultures were in the exponential 
growth phase, the growth medium was not depleted for glutamine, lactate levels were 
still modest, and the clones had released a dynamic range of FVIII to the growth 
medium. 
 
Following RNA extraction the samples were analyzed by next generation sequencing. 
The three highest FVIII producing cell lines, three of the medium producing cell lines 
and the three cell lines with no productivity of FVIII were analyzed in triplicate in order 
to assess the reproducibility. On average, 31.3 million read pairs were sequenced from 
each library. Hereof, 2-6 % of the reads aligned to the exogenous F8 and dhfr 
sequences, making F8 and dhfr mRNA the most abundant transcripts in the present 
clones. 
 
3.2 The transgene expression level did not correlate with amount of secreted protein  
The expression level of F8 and dhfr were quantified as sequenced fragments per kb  of 
exon per million fragments mapped (FPKM), a normalized value allowing comparison 
of mRNA/cDNA levels from genes of different lengths and from RNA samples giving 
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rise to different numbers of reads [32]. The clones analyzed in triplicate exhibited only 
little internal variation both with regards to the expression level of F8 and dhfr and 
with regards to the FVIII productivity, demonstrating the reproducibility and 
robustness of the assays. For each of the FVIII producing clones (clone 1-11), the 
expression ratio of F8 and dhfr was close to one (Figure 3B). This is in agreement with 
the bicistronic mRNA expression strategy utilized in the present clones and described 
in greater detail below. 
 
The expression of F8 RNA was found not to correlate with the productivity neither as 
expressed as mU FVIII/cell/48h (Pearson correlation = 0.03) nor as ng FVIII/cell/48h 
(Pearson correlation = 0.24). In contrast the expression level of dhfr mRNA showed a 
small tendency to correlate negatively (Pearson correlation = -0.55) (Figure 3B). Among 
the three non-producing clones (12, 13, and 14), the F8 and dhfr expression levels 
were highly variable. Interestingly, the F8 RNA expression level of clones 12 and 13 
were not reduced compared to the highest producing clones, whereas that of clone 14 
was substantially reduced compared to all other clones (Figure 3B). The expression 
level of dhfr in the non-producing clones was similar to or higher than those of the 
FVIII producing clones (Figure 3B). In conclusion, the levels of F8- or dhfr-coding 
mRNAs do not seem to determine FVIII productivity. The findings were validated using 
qRT-PCR making cDNA from the same RNA samples sent for RNA sequencing showing 
the same overall level of F8 and dhfr mRNA among the clones (Figure 3C).  
 
3.3 The transgene was found to be truncated in a number of clones 
In order to further characterize the mRNAs transcribed from the F8 and dhfr 
expression cassette, the read depth distribution over the F8-dhfr expression cassette 
was analyzed for each of the 14 clones. Starting upstream, the present expression 
cassette comprises the adenovirus-2 major late promoter, the adenovirus-2 late mRNA 
tripartite leader, a 3’ end and 5’ end intron sequence with splice junction, the ORF of 
F8 with a minimal artificial B-domain [23], an internal ribosomal entry site (IRES), the 
dhfr ORF, and a poly A signal, similar to constructs used elsewhere [24,25] (Figure 3A). 
The read depth distribution was essentially identical for the three highest yielding 
clones (clone 1-3). The entire F8 and dhfr ORFs and the connecting IRES element were 
transcribed (Figure 3D top). At the 5’ end, the tripartite leader and the UTR upstream 
of the F8 ORF, but not the separating intron sequences were transcribed, suggesting 
that the intron sequences were indeed removed from the nascent mRNA by splicing 
(Figure 3D top). Likewise, the read depth distribution was very similar among the eight 
lower producing clones (clone 4-11), but differed from the three highest producing 
clones, as the tripartite leader did not appear to be transcribed (Figure 3D). The read 
depth distribution of the three non-producing clones (clones 12-14) explained the 
failure of these clones to produce FVIII. Clone 12 and 13 only partially transcribed the 
F8 ORF, as an upstream portion containing the initiation codon was not transcribed. 
Clone 14 did not appear to transcribe any part of the F8 ORF (Figure 3D). In contrast, 
the dhfr ORF was transcribed in all 3 clones, explaining the capacity of the non-
producing clones to survive MTX selection. 
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In order to validate the truncations suggested by RNA sequencing, the transgene 
regions integrated into the genome of clone 1, 8, 12, 13 and 14 were sequenced using 
TLA. It was possible to identify a specific insertion locus on the CHO-K1 reference 
genome for two of the five clones. The fragments found in the genome corresponded 
well with the results found by RNA sequencing (Table 1). Clone 1 was shown to have all 
of the expected sequence inserted. In the genome of clone 14 472bp of the promoter 
region was found flanking the entire dhfr ORF thus explaining the transcription of the 
truncated transcript from the promoter present on the plasmid. Clone 8 was found to 
be devoid of promoter and tripartite sequence. Surprisingly, at the locus found by 
targeted sequencing to be the insertion site of the transgene, RNA sequencing data 
found expression from only clone 4-11 (Figure 4A). The region downstream of the 
insertion locus was transcribed, but the expression level rapidly dropped to zero right 
at the suggested insertion site indicating that this region of the genome is the 
promoter region for the inserted transgene. Using genomic PCR it was found that the 
transgene had indeed integrated into this region at the same position in clone 7 and 
clone 8 (Figure 4B). 
 
4 Discussion  
In the present study, we describe deep sequencing analysis of mRNA transcribed from 
the exogenous F8 and dhfr expression cassette of clonal CHO cell lines exhibiting a 
dynamic range of recombinant FVIII productivities. The expression vector allows the 
synthesis of a single bicistronic mRNA comprising the adenovirus-2 late mRNA 
tripartite leader followed by both the F8 and the dhfr coding ORFs separated by an 
IRES element, allowing translation of both ORFs from the same mRNA. In the present 
clones, the expression ratio of F8 and dhfr RNA’s was close to 1, suggesting that the F8 
and dhfr expression is indeed coupled. For comparison, dhfr transcripts were more 
abundant than transcripts from the gene of interest in a previous next-generation 
sequencing study on a BHK recombinant protein production cell line [21], suggesting 
that in the latter cell line, expression of dhfr and the gene of interest were less strictly 
coupled. 
 
Among the clones analyzed in the present study, the level of F8-dhfr coding mRNAs did 
not determine FVIII productivity. The clones were all adapted to growth in the 
presence of MTX. In our hands, amplification using MTX is required to reach the 
optimal FVIII productivity, so the level of F8 coding mRNA obviously plays a role for 
FVIII productivity, just as seen with antibodies [33]. In the present study however, the 
F8-dhfr mRNA level required for growth in the presence of MTX most likely exceeded 
the level required for saturating the FVIII production machinery of the highest yielding 
clones. Instead, the composition of the mRNA molecules transcribed from the F8-dhfr 
expression cassette appeared to play a key role in determining the FVIII productivities 
of the clones. The read depth distribution over the F8-dhfr expression cassette 
describes the number of reads aligning with the individual nucleotides in the 
expression cassette. Thus, the read depth shows the composition of the F8-dhfr coding 
mRNAs based on thousands of mRNA molecules from each clone. In clones not 
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producing detectable FVIII, the mRNA transcribed from the F8-dhfr coding expression 
comprised the entire dhfr ORF, but a 5’ end fragment of the F8 ORF or the entire F8 
ORF was missing. This explains the capacity of these cells to grow in the presence of 
MTX without producing FVIII.  
 
The Targeted Locus Amplification Technology has previously been used to elucidate 
transgene insertion loci and transgene composition [27]. In the present study TLA 
analysis were able to provide an explanation for the expression of truncated F8-dhfr in 
clone 14 as a fragment of the promoter had been integrated on chromosome five 
flanked by dhfr leading to expression of a truncated transcript. In the case of clone 8, 
12 and 13 no fragments of the promoter was detected thus suggesting that an 
endogenous promoter was used to induce transcription. In the case of clone 8, it was 
seen that the region flanking the insertion site is expressed and that the expression 
level drop to zero at exactly the position suggested as the transgene insertion locus. 
Thus it seems that this region, which appears to be silent in the other clones, is able to 
induce transcription in order to allow the cells to survive under selection. Peculiarly, it 
is seen that all eight lower producing clones show the same signature from this region 
indicating that all these clones are subclones from a single cell, which inserted the 
truncated transgene into this particular locus. A similar mechanism explaining the 
transcription of truncated F8-dhfr in clone 12 and 13 is still to be elucidated but it was 
found that at the suggested insertion regions these clones showed expression profiles 
different from all other clones (data not shown), which could indicate a similar 
mechanism as in the case of clone 8.  
 
Whether the plasmid was truncated prior to integration or during integration is not 
possible to tell. Earlier reports have found transgenes can undergo homologous but 
non-conservative recombination resulting in truncations followed by illegitimate DNA 
integration by a DNA repair-mediated integration process into the host genome [34-
37]. The most important aspect in relation to the data at hand is the consequence of 
only applying selection pressure for one specific part of the transgene, namely 
transcription of the dhfr ORF. The data shows that in the case the cells are in any way 
able to produce the selection marker without the transgene there is a clear selection 
pressure favoring these, thus a dual selection system conferring selection for both the 
region downstream and upstream of the F8 ORF could reduce the probability of 
encountering instances such as the one described here.  
 
Among the FVIII producing clones, the three highest yielding clones distinguished 
themselves from the lower yielding clones by the presence of F8-dhfr coding mRNA 
with the adenovirus-2 late mRNA tripartite leader. The tripartite leader is reported to 
optimize the translation efficiency by translation independent from CAP-binding 
proteins [38,39], and the present findings suggests that the tripartite leader can 
indeed increase the yields of recombinant FVIII translated from a lower level of F8-
mRNA (Figure 3B). It has been shown that introduction of the tripartite leader 
upstream of firefly luciferase or interferon gamma in transiently transfected CHO-K1 
cells lead to an increase in protein productivity of 3.6 and 7.6 fold respectively 
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although it decreased the productivity of an antibody in the same cell line indicating 
that the impact of addition of the tripartite leader is gene-specific [40].  
 
The current results suggest that development of mammalian production cell lines may 
be facilitated by testing for the presence of the expected 5’ mRNA end encoding the 
gene of interest (as in Figure 3C top). Cell line development typically involves the 
generation of non-clonal pools of transfected cells that are resistant to selection and 
cloning of one or more pools. When choosing among several cell pools, we often 
choose to clone the pool with the highest yield of our protein of interest. However, the 
yield of the cell pool does not give an impression on the distribution of the yields 
among the individual clones in the pool. Testing cell pool mRNA for a probe annealing 
to the expected transcriptional start site, may provide a better basis for choosing cell 
pools containing the highest yielding clones as it may indicate proper integration into 
the genome without extensive truncation of the transfected plasmid.  
 
In conclusion, deep sequencing is an extremely powerful and robust method for 
quantification and analysis of the mRNAs transcribed from the gene of interest and the 
selection marker inserted in cell lines for production of recombinant proteins. The 
readout is based on several thousand mRNA molecules transcribed from the same 
expression cassette, giving a detailed and highly representative picture of the mRNA 
population revealing the transcriptional start end termination site as well as intron 
splicing. Using RNA sequencing in contrast to microarrays thus allow for an insight into 
the use of the plasmid used for heterologous expression in addition to information 
regarding the general transcriptome.   
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Table 1. Detected ranges of transgene in RNAseq data and by targeted sequencing. 
Name RNAseq DNAseq Chromosome 
Clone 1 303 - 7,347 1 - 7,776 2a) 
Clone 8 1,507 - 7,327 1,313 - 8,262 X 
Clone 12 2,717 - 8,185 2,705 - 8,261 7 a) 
Clone 13 3,897 - 7,405 3,854 - 7,643 5 a) 
Clone 14 6,387 - 7,285 
583 - 1,055, 
6,388 - 7,646, 
4,382 - 4,549, 
8,757 - 8,900 
5 
 
a) A certain region is most likely the insertion locus but no breakpoint reads in an 
individual scaffold in the (incomplete) CHO-K1 reference genome was identified.  
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Figure legends 
 
Figure 1. CHO DXB11 cells were transfected with a plasmid encoding FVIII and were subsequently single cell diluted. (A) The productivity of 62 CHO clones. Each bar represents an 
individual clone and clones numbered 1-14 were selected for further analysis. FVIII 
productivity was calculated as units recombinant FVIII (COA) released per cell per day, and is 
shown as percentage of the clone with highest productivity. (B) Western blot showing 
presence of FVIII protein in cell lysates from clone 1-14. 
 15 
 
Figure 2. Growth and FVIII production of 14 selected CHO DXB11 clones. (A) Cultures were set 
ups seeded at 3x10e5 cells/ml and monitored during cultivation for viable cell count. Error bars 
indicate standard deviation of biological replicates. (B) The glutamine, glucose, and lactate 
 16 
levels found in the growth medium (data from all cultures collapsed into one graph). Error bars 
indicate standard deviation from cultures from all 14 clones. (C) Production titer measured as 
units of active FVIII in the growth medium relative to maximum. Error bars indicate standard 
deviation of biological replicates. 
 
Figure 3. F8 and dhfr mRNA levels across the 14 analyzed clones. (A) Overview of transgene 
composition. qPCR primer targets used in (C) are marked with grey lines. (B) F8 and dhfr 
expression level based on RNA sequencing in the CHO DXB11 clones (1-14) versus productivity. 
FVIII productivity is calculated as units recombinant FVIII released per cell within the first 48 
hours of cultivation, and is shown as percentage of the clone with highest productivity. (C) 
Tripartite leader, F8 and dhfr expression level based on qRT-PCR in the CHO DXB11 clones (1-
14) versus productivity. (D) Read depth distribution over each basepair of the F8-dhfr 
expression cassette on the transfected plasmid. Typical results show for each group. From the 
top: clone 1 (High FVIII producing cell line), clone 8 (Medium FVIII producing cell line), clone 12 
(non-producing cell line), clone 13 (non-producing cell line) and clone 14 (non-producing cell 
line). Representative clones for the various RNA signatures shown.  
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Figure 4. The transgene integration site of clone 8. A) Read depth distribution for each base 
pair of the 20 kb region surrounding the suggested insertion site of clone 8 (vertical line) on 
scaffold NW_003615608.1 position 140838 in RNA sequencing data for  all 14 clones. (B) 
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Genomic PCR amplifying a 222bp region of gapdh as positive control in CHO DXB11, clone 3, 
clone 7 and clone 8. PCR 1 and 2 both span from the transgene to flanking genomic region.  
 
 
 
 
 19 
